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Populärvetenskaplig sammanfattning 
Prostatacancer är en av de vanligaste cancertyperna i västvärlden och drabbar runt tiotusen 
män per år i Sverige. Prostatan är en litet organ som ligger under urinblåsan hos män och vars 
funktion är att producera och utsöndra viktiga komponenter i sädesvätskan. På grund av den 
stora mängden lidande och de omfattande ekonomiska kostnader som prostatacancer ligger till 
grund för i samhället så är behovet av forskning inom området mycket stort.  
Cancer i prostatan är i sig inte dödligt. När prostatacancer har dödlig utkomst så är det 
uteslutande i fall där cancern har spridit sig till viktigare organ, så som ben, lungor eller 
lymfkörtlar. Att cancer sprids kallas metastas och är en komplex biologisk process som består 
av flera distinkta steg, och som påverkas av många olika faktorer. Tidigare har forskare vid 
University of Michigan, Ann Arbor visat att metaboliten sarkosin ansamlas i stegvis värre fall 
av prostatacancer, framför allt då cancern går från att befinna sig lokalt i prostatan till att 
sprida sig till andra vävnadstyper. I deras artikel beskriver de sarkosin en onkometabolit, det 
vill säga en metabolit som är kapabel att driva cancers förvärring. Dessutom hävdar de att 
sarkosin kan användas som analyt i av blod- eller urinprover för att påvisa cancer. Resultaten 
kring sarkosinets roll inom biomedicinsk analys har ifrågasatts, men resultaten kring dess roll 
som onkometabolit har inte undersökts i detalj ännu.   
I experimentet som ligger till grund för den här rapporten har vi tittat närmare på hur närvaron 
av sarkosin påverkar prostatacellers metabolism. Prover förbereddes genom att inkubera celler 
i provrör tillsammans med sarkosin eller med någon av tre närbesläktade metaboliter; glycin, 
dimetylglycin och alanin. Analyserna utfördes med hjälp av en metod som kallas NMR-
spektroskopi (Nuclear Magnetic Resonance-spektroskopi), vilket är en kraftfull analysmetod 
som används för att analysera kolföreningar. Våra resultat indikerar att sarkosins påverkan på 
celler har en omfattande effekt på cellens metabolism. Flera viktiga cellulära funktioner, så 
som energiomsättning, användning av aminosyror samt fettomsättning påverkas då sarkosin 
tillsatts. 
Resultaten som har genererats inom den här studien kan i framtiden ligga till grund för 
framsteg med klinisk betydelse. Många av de viktigaste etablerade läkemedlen mot cancer 
angriper cancerns förmåga att ställa om cellens metabolism och det är en måltavla för forskare 
som avser att hitta nya läkemedel. En ny infallsvinkel på cancermetabolism i en av de kliniskt 
viktigaste cancertyperna har därför stor betydelse. 
Abstract 
Prostate cancer is one of the most common form of human cancer in the world and the most 
common form of cancer in men in the Western world. There are many molecular factors of 
prostate cancer, both proteins and metabolites. A 2009 study by Sreekumar et al found that the 
N-methyl form of glycine, also known as sarcosine, is correlated with more advanced prostate 
cancer and that it could potentially be driving cancer progression. Since then, a transcriptomic 
analysis has revealed some of the genes that might be involved in sarcosine-driven prostate 
cancer progression but the exact mechanism is as of yet not known. We set out to examine the 
effect of treatment with sarcosine, glycine, N,N-dimethylglycine and alanine on the 
metabolism of cultured prostate cancer cells and non-malignant immortalized prostate cells. 
Here we demonstrate that sarcosine changes the metabolism of prostate cancer cells and that 
broad cellular functions, such as energy metabolism, pyrimidine metabolism and amino acid 
metabolism are affected. Using NMR metabolomics we showed that the cellular 
concentrations of glucose, choline, O-phosphocholine, creatine, creatine phosphate, proline 
and other metabolites are altered as a result of the presence of sarcosine. Previous 
transcriptomic data has pointed towards the cell cycle as being involved in a potential 
mechanism of sarcosine-induced prostate cancer progression. Our data suggests significant 
metabolic involvement as well. Metabolism has seen a resurgence recently in cancer research 
in general and in this research we demonstrate that is worth exploring deeper in prostate 
cancer specifically.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Prostate cancer is the third most common cancer in the world and the most common in the 
developed world. Every year almost 10,000 new cases are diagnosed and around 2,500 men 
die from prostate cancer malignancies in Sweden (Cancerfonden, 2013). The prostate is a tiny, 
excreting gland in the male reproductive system located underneath the bladder. It consists of 
three main cell types, epithelial luminal cells, basal stem cells and neuroendocrine cells (Fig. 
1). Cancer in the prostate almost exclusively occur in the prostate epithelial cells, which are 
responsible for secreting many important component of seminal fluid (Toivanen and Shen, 
2017).  
 
 
Figure 1: Representative depiction of a prostate epithelium. Large, connected epithelial cells 
bound together by tight junctions to form a barrier that is difficult to permeate for most 
molecules. Basal stem cells hold the epithelium anchored to the basement membrane as well 
divide into new epithelial cells, and nerve cells regulate prostate contraction via smooth 
muscle fibers encircling gland. Adapted from Toivanen et al, Development, 2017, with 
permission from the publisher.  
Tumors in the prostate are generally not lethal. However, high-grade tumors can eventually 
become metastatic and invade other tissues such as lung-, bone-, lymph- and liver tissue, 
which are all potentially lethal sites (Sartor and de Bono, 2018). Because of the human 
suffering and the high amount of resources that are allocated to fighting prostate cancer, 
research in this area is desperately needed.  
 
 
 
Molecular biology of prostate cancer 
The exact mechanism by which cancer occurs is not completely understood, and appears to be 
diverse, but it involves sequential mutations resulting in similar phenotypic changes. There 
are different factors governing the rate at which mutations occur, such as the state of DNA 
repair systems, the presence of carcinogens, and metabolic factors (Hanahan and Weinberg, 
2011). Some mutations are more common than others in distinct tissue types. Common 
genetic factors of prostate cancer are general oncogenes and tumor suppressors, such as 
phosphatase- and tensin homolog (PTEN), signal transducer and activator of transcription 3 
(STAT3) and c-Myc (Shand and Gelmann, 2006; Pourmand et al., 2007; Gandhi et al., 2018). 
Under healthy physiological conditions, a balance between tumor suppressors and oncogenes 
exists. This balance is often disturbed in cancer. PTEN, STAT3 and c-Myc are master 
regulators of cell growth and in cancer their roles are to enable the cells to proliferate 
endlessly. The role of PTEN under normal physiological conditions is to end the 
PI3K/Akt/mTOR cascade, which is a downstream response to growth signaling, by 
dephosphorylating phosphatidylinositol-3,4,5-triphosphate (Pourmand et al., 2007). STAT3 
and c-MYC are transcription factors that are activated by growth signaling and which regulate 
genes involved in cell growth. When Stat3 is knocked out the progression of prostate cancer 
increases, and a higher expression might have a protective effect (Priolo et al., 2014; Pencik 
et al., 2015). In some cancers, the activities of these proteins are altered to affect the 
metabolic state of the cell in important ways, such as increasing the rate of glycolysis and the 
oxidation of fatty acids through β-oxidation (Eidelman et al., 2017). 
In prostate cancer specifically, two of the most commonly mutated genes are the androgen 
receptor (AR) and the ETS-related gene (erythroblast transformation specific-related gene, 
ERG) (Packer and Maitland, 2016). Under normal physiological conditions these two 
transcription factors are involved in regulating hundreds of genes related to cell proliferation, 
differentiation, inflammation and apoptosis. The AR is activated by binding to either 
testosterone or dihydrotestosterone and this activation results in changes in gene expression 
that leads to cell proliferation (Massie et al., 2011). ERG is expressed in the entire body but a 
common gene fusion with the promoter region of the gene TMPRSS2, which results in 
dramatic overexpression, is found in over 50% of prostate cancer cases (Tomlins et al., 2008; 
Li and Vederas, 2018). Both of these transcription factors respond to androgen signaling and 
regulate genes that encode metabolic enzymes (Massie et al., 2011). It has been shown that 
they cause profound changes in cellular metabolism once overexpressed in cancer. A feature 
of prostate cancer that generally results in poor patient outcomes is androgen independence. 
Androgen independence occurs when either of these two genes overcomes the need for the 
presence of androgen at physiological concentrations for their activity. This can occur through 
overexpression as a result of a few known biological mechanisms, such as through gene 
duplications, through point mutations resulting in being constitutively active or through 
mutations resulting in increased androgen levels (Karantanos, Corn and Thompson, 2013) . 
Cancer metabolism 
A central aspect of all cellular metabolism that is shared by all cells is the conversion of 
glucose into energy. The first step of this conversion is through glycolysis, where glucose is 
converted to pyruvate through a series of ten reactions. Pyruvate then enters the tricarboxylic 
acid cycle (TCA cycle) via a reaction known as the linking reaction. In most human cells, 
products of the TCA cycle are used to produce energy through oxidative phosphorylation. 
Some substrates of the reactions of glycolysis are also used as substrates for a secondary 
pathway called the pentose phosphate pathway. While glycolysis and the TCA cycle are 
oxidative pathways that produce energy, the pentose phosphate pathway is a pathway that 
produces substrates for biosynthetic pathways for many nucleotides and amino acids. These 
three components together; glycolysis, the TCA cycle, and the pentose phosphate pathway are 
called central-carbon metabolism and form the backbone of the metabolism of all known 
forms of life (Noor et al., 2010). Apart from the central carbon metabolism, each distinct cell 
type has unique aspects to its metabolism. One example in humans is that many cells can 
sustain their TCA cycle metabolism through the oxidation of fatty acids produced by the liver 
and stored in adipocytes, as is the case during starvation (Perry et al., 2018). Another example 
is epithelial cells which are replaced often and therefore need to divide often have a more 
active nucleotide metabolism than terminally differentiated cells such as neurons or 
osteocytes (Aird and Zhang, 2015). 
It is only recently that metabolism has resurged in cancer research as not only a symptom of 
cancer but as a phenomenon capable of driving cancer progression and affecting outcomes. 
Cancer cells rewire their metabolism in order fuel their increased growth rates (Hanahan and 
Weinberg, 2011). It is believed this rewiring is done partly through changes in the expression 
or activity of regulator proteins, such as transcription factors or signaling proteins, and partly 
through changes to metabolic enzymes and transporters which have a direct effect on cellular 
metabolism. An example of this has been demonstrated in prostate cancer by the metabolism 
of citrate. Healthy prostate tissue accumulates zinc, which inhibits the TCA cycle enzyme 
aconitase and results in accumulation of citrate which is subsequently used for lipogenesis or 
excreted into the seminal fluid. In prostate cancer cells, the intracellular levels of zinc are 
reduced. This results in an increased aconitase activity, a reduced concentration of citrate and 
a higher rate of TCA cycle flux (Eidelman et al., 2017). In this regard, prostate cancer stands 
out compared to most other cancers in which TCA cycle flux is reduced through the so-called 
Warburg effect (Vander-Heiden et al., 2009).  
Another prostate cancer-specific metabolic alteration takes place in development of androgen 
independence. In healthy prostate epithelial cells, androgen signaling activates the synthesis 
of vital lipids (Butler et al, 2016). Lipids are necessary for growing cancer cells. Loss of 
androgen signaling can therefore result in growth inhibition of cancers which still rely on 
androgen signaling. In order for prostate cancer to become androgen independent a significant 
shift in the cellular metabolism of lipids needs to take place in which the biosynthesis of lipid 
molecules can occur without the presence of androgen. Malignant prostate cells overexpress 
many genes involved in lipogenesis, such as fatty acid synthase (FASN), sterol regulatory 
element binding protein 1 (SREBP1) and steroyl-CoA desaturase. The activities of these 
proteins, FASN in particular, have also been shown to be increased in many prostate cancers 
(Butler et al, 2016).  
Metabolomics 
Metabolomics is an analytical approach in which the concentrations of small, organic 
molecules are measured in a biological sample. It relies on analytical chemistry techniques, 
such as mass spectrometry and NMR spectroscopy. While mass spectrometry is and more 
sensitive, NMR spectroscopy offers one main advantage, which is that it has significantly less 
instrumental variation. The smaller amount of variation makes it ideal when measuring small 
differences. Since NMR spectroscopy is not destructive, these two methods can be used 
together. Traditionally, metabolomics has been used as a method for finding biomarkers of 
various diseases. However, that has changed lately and it has become a more commonly used 
method for researchers interested in exploring the cellular metabolism of a given sample 
(Johnson et al, 2016). There are different methods that gather various kinds of biological data 
about a sample, such as genomics, transcriptomics and proteomics. The foremost advantage of 
metabolomics as compared with other omics-techniques is that it shows the actual state of the 
cell. Metabolites are the substrates and the products of most biological processes and other 
biological changes such as alterations in gene expression or protein activity ultimately result 
in changes to the pool of metabolites. 
One-carbon metabolism and sarcosine 
Many of the biosynthetic processes in the cell requires the addition, activation or transfer of 
single carbon units, which are present in the cell in the form of methyl-groups carried by the 
enzymatic co-factor folate. Folate-carried methyl-groups are required for methylation of DNA 
for epigenetic silencing, biosynthesis of amino acids and nucleotides and maintaining the 
redox balance through NADP+/NADPH cycling. The methyl-groups on folate have slightly 
different energy-levels depending on to what extent the methyl-groups are oxidized or 
reduced (Ducker and Rabinowitz, 2017).  
Figure 2: Scheme of human folate metabolism. (Adapted from Rabinowitz, 2017, with 
permission from publisher). 
Folate gets its high-energy methyl groups primarily from the metabolism of the non-essential 
amino acid serine (Fig. 2). Serine is metabolized into glycine by the enzyme serine 
hydroxymethyltransferase (SHMT), giving one hydroxymethyl-group to THF. The methyl-
group can then be used to methylate S-adenosylhomocysteine to make S-adenosylmethionine 
(SAM), which can be used as a co-factor by the enzyme glycine N-methyltransferase 
(GNMT) to methylate glycine into sarcosine. SHMT is present in mitochondria, but the 
mitochondrial need for single carbon units is small. Most of the use of single carbon units is 
taking place in the cytoplasm, making the localization of their production in the mitochondria 
counterintuitive. The reason this division is taking place is not known. One hypothesis is that 
it decouples serine-dependent production of single-carbon from glycolysis (Amelio et al., 
2014; Ducker and Rabinowitz, 2017).  
Figure 3: 
Metabolites in 
the pathway 
breaking 
catabolizing 
betaine through 
serial 
demethylation 
into glycine. 
The enzymes 
regulating the 
concentration of 
sarcosine present in the cell are GNMT, which methylates glycine to form sarcosine, sarcosine 
dehydrogenase, which demethylates sarcosine to form glycine, and dimethylglycine 
dehydrogenase, which demethylates N,N-dimethylglycine to form sarcosine (Fig. 3). GNMT 
is present in the cytosol, whereas sarcosine dehydrogenase is present in the matrix of 
mitochondria. Glycine can be methylated in the mitochondria or in the cytoplasm, transported 
across the mitochondrial membrane as sarcosine and subsequently be demethylated to 
regenerate glycine. Both GNMT and sarcosine dehydrogenase are regularly mutated in 
cancers (Tibbetts and Appling, 2010; Ducker and Rabinowitz, 2017) GNMT is also regulated 
largely by the androgen receptor, which makes it more likely to be overexpressed in prostate 
cancer. This results in increased sarcosine concentrations and also increased mitochondrial 
one-carbon metabolism (DebRoy et al., 2013; Khan et al., 2013; Ottaviani et al., 2013). 
Description of the problem 
In 2009 a paper was published in Nature by Sreekumar et al suggesting a role of sarcosine in 
prostate cancer progression (Sreekumar et al., 2009). Using an untargeted metabolomics 
approach the authors had discovered six metabolites that had increasing concentrations from 
benign prostate tissue to localized prostate cancer tissue, and from localized prostate cancer 
tissue to metastasized cancer tissue with origins in the prostate. One of these metabolites was 
sarcosine so they hypothesized that sarcosine had a role in the progression of prostate cancer. 
By treating cells with sarcosine they could show that sarcosine induced an invasive phenotype 
in benign prostate epithelial cells. They could also demonstrate that glycine could induce an 
invasive phenotype but to a lesser extent. The effect of glycine disappeared when the enzyme 
converting glycine to sarcosine, GNMT, was knocked down, concomitant with a decrease in 
the concentration of sarcosine below the limit of detection. This suggested that the effect 
came from sarcosine specifically. 
In their paper Sreekumar et al suggested that sarcosine could be used as a biomarker for 
aggressive metastatic prostate cancer progression, which has been questioned in other papers 
(Jentzmik et al., 2011; Khan et al., 2013; Ankerst et al., 2015). Other groups have attempted 
to find epidemiological data supporting the use of sarcosine as a biomarker but have failed to 
do so, however it should be noted that they only looked for correlation between the levels of 
sarcosine and cancer prevalence in general. In 2016 the first paper came out that looked 
deeper into the mechanistic aspects of sarcosine-induced invasiveness. Heger et al examined 
the transcriptional profiles of prostate cancer xenografts grown with sarcosine and could 
demonstrate profound alterations in gene expression compared to xenografts treated with 
alanine. The genes with the biggest change in expression were genes involved in cell cycle 
progression (Heger et al., 2016). While this transcriptomic analysis generated intriguing clues 
to a mechanism for sarcosine-induced invasiveness, it did not give a clear answer.  
Figure 4: The missing piece (purple) from past experiments (blue and red). In their original 
publication Sreekumar et al conducted metabolomics experiments on patient samples and 
both Sreekumar et al and Heger et al found phenotypic alterations as a result of incubation 
with sarcosine. The purpose of the experiment underlying this report was to conduct 
metabolomics analyses on cell cultures to explore metabolic effects of sarcosine treatment. 
The purpose of this experiment was to examine whether or not sarcosine had a metabolic 
effect on prostate epithelial cell cultures (Fig. 4). We hypothesized that a metabolic effect 
brought on by sarcosine treatment might be required to support the change in phenotype 
reported by Sreekumar et al and the physiological alterations reported by Heger et al. 
Therefore, we decided to probe the effects of sarcosine on the metabolism of two prostate 
cancer cell lines, one androgen sensitive and one androgen insensitive, and one benign 
prostate cell line as a control.  
Materials and methods 
Figure 5: The experimental set up for the cell growth and subsequent metabolomics analysis 
of prostate cancer cell cultures treated with increasing concentrations of amino acids. 
Cell growth 
A non-malignant immortalized prostate epithelial cell model RWPE-1 and two human 
metastatic cancer cells, PC3 (androgen independent) and LNCaP (androgen dependent), were 
confirmed to be free for mycoplasma contamination. RWPE-1 cells were cultured in 
Keratinocyte-SFM (Gibco, Life Technologies) medium supplemented with recombinant 
human Epidermal Growth Factor and Bovine Pituitary Extract (Gibco, Life Technologies). 
LNCaP and PC3 cells were cultured in RPMI 1640 (Gibco, Life Technologies) medium 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. Cells were seeded in 
6-well plates in 2 ml of respective medium and incubated at 37oC to reach 60-70%
confluency.
The growth medium was aspirated and cells were incubated in 2 ml growth medium with 0 
µM, 10 µM, 25 µM or 50 µM of glycine (Sigma Aldrich), L-alanine (Sigma Aldrich), 
Sarcosine (Sigma Aldrich) or N,N-Dimethylglycine (Sigma Aldrich) separately for 48 hours 
at 37oC and 5% CO2 (Fig. 5). To harvest the cells, the conditioned medium was collected from 
the plates and the cells were washed with PBS. The cells were then scraped off the bottom of 
the wells, transferred into 1.5 ml centrifuge tubes, centrifuged and flash frozen in liquid 
nitrogen. All samples were stored at -80oC until they were sent from Vienna, Austria to 
Uppsala, Sweden on dry ice. In total 284 samples were generated. 
Sample preparation 
The samples were stored in -80oC and consisted of 1.5 ml centrifuge tubes with a solid pellet 
in the bottom. Extraction of cell pellets was done in batches of 24 samples per batch. The 
order of the samples was randomized using the random-generator at http://random.org. Before 
the extraction was started methanol was cooled to -20oC and taken out immediately before 
being used. A batch of samples were removed from -80oC and placed on ice. 500 µl of cool 
methanol was added on top of the pellet and the pellet was physically broken up by the pipette 
tip. Once the pellet was broken up into small pieces the methanol suspension was transferred 
to a 10 ml glass tube. The centrifuge tube was cleaned by another 500 µl- and then 1000 µl 
twice of cool methanol being added to the tube and then transferred to the same glass tube to a 
total of 3 ml of methanol suspension. The tubes were sealed with a rubber stopper and 
covered with Parafilm. 
Figure 6: Schematic overview of the extraction protocol used to extract metabolites from cell 
pellets. 
The cells were lysed by placing the glass tubes in a cooled ultrasonic bath for 30 minutes. 
After the ultrasonic bath the tubes were vortexed briefly and then placed at -80oC for 2 hours 
and then placed at room temperature for 15 hours. After the lysis procedure the 3 ml of 
methanol suspension was transferred to 1.5 ml centrifuge tubes and centrifuged at 10,000 x g 
for 10 minutes in 1 ml aliquots. The supernatants were moved to a new glass tube and the 
methanol was dried off under continuous flow of N2 for 4-5 hours (until all the liquid was 
gone and then one extra hour). Left in the glass tube was a white precipitate on the side of the 
glass wall. The precipitate was suspended in 570 µl of 0.135M of phosphate buffer at pH 7, 
50 µl of D2O and 30 µl of 5.8 mM TSP internal standard (Trimethylsilylpropanoic acid, 
Larodan). 
 
 
NMR spectroscopy and statistical analysis 
Analysis was performed using Bruker 600 mHz (Karlsruhe, Germany) with a 5-mm cooled 
probe. The NMR experiment was performed at 25oC with 400 scans and 65536 data points 
over a spectral width of 17942.58 Hz. The acquisition time was 1.83 s. The spectral baseline 
and phase were corrected manually using the built in features in Topspin 3.5.7. 
 
Figure 7: Scheme of the data analysis pipeline utilized to explore the data generated in the 
experiment presented in this report. 
Spectral data was analyzed statistically using primarily SIMCA 14 (UMETRICS, Umeå, 
Sweden) and MiniTab. The NMR spectra were divided into 0.01 ppm wide sections (buckets) 
which were integrated and then divided by the integral of the entire spectra in Amix 3.9.7 
(Bruker Biospin GmbH). The areas between 2.93-2.97 ppm, 3.04-3.08 ppm, 3.14-3.19 ppm 
and 3.85-3.89 ppm, containing the peaks from the buffering agent HEPES, as well as 4.50-
5.20, which corresponds to the water peak, were excluded. Once the bucket table had been 
extracted multivariate statistical modeling in SIMCA 14 was done to find individual buckets 
that differed between the different groups. A high threshold of VIP – cv > 1 was set to make 
sure that buckets were meaningful. Once a bucket had been identified to cause separation in a 
partial least squares-discriminant analysis (PLS-DA) model the next step was to determine 
what metabolite that bucket corresponded to. This was done using a combination of Amix 
3.9.7, Chenomx Profiler 8.31 (Chenomx Inc.) and the 1H-spectral database at the Human 
Metabolome Database (www.hmdb.ca). Once a metabolite had been suggested to be different 
in the multivariate models it was confirmed using Minitab 17.3.1 (Minitab Inc.). ANOVA-
tests followed by post-hoc Tukey-tests were used to confirm the statistical significance of the 
finding. Prior to the univariate statistical analysis an Anderson-Darling normality test was 
done on the data to ensure normal distribution, which was the case in all statistically 
significant analyses.  
Results 
Comparisons were made within each cell line individually. Within each cell line, each 
treatment was analyzed individually to assess the metabolic effects of the treatment with 
regards to the concentration of amino acid added. Principal component analyses (PCA) were 
conducted to eliminate outliers and partial least squared discriminant analyses (PLS-DA) were 
used to discover buckets corresponding to metabolites that differentiated between the 
samples. 
Figure 8: Summary of the results from the comparisons of metabolic profiles with 0 µM, 10 
µM, 25 µM and 50 µM of metabolite. For PC3 grown with sarcosine, and for LNCaP grown 
with sarcosine and N,N-dimethylglycine, differential concentrations of individual metabolites 
could be detected (green). For both PC3 and LNCaP grown with alanine, significant models 
could be produced with multivariate statistics but no individual metabolites differed 
significantly between the groups (orange). For all other parts of the experiment, no 
statistically significant effects were detected (grey).   
A summary of the results can be found in figure 8. Metabolic shifts were detected in PC3 and 
LNCaP, but not in RWPE-1. 
RWPE-1 
To see the metabolic effects of treatment with sarcosine, glycine, N,N-dimethylglycine an 
alanine on non-malignant prostate cells, the buckets from the RWPE-1 cells were compared 
with multivariate statistics. The area under the spectrum for each bucket was used in 
multivariate analysis to compare the metabolic effects of the different concentrations of 
treatment metabolite. No components were fitted in PLS-DA models of the data from RWPE-
1 cells. The bucket data corresponding to metabolites found to be differential in the other cell 
lines were also examined in RWPE-1 but no significant changes were found. 
17
LNCaP 
No significant differences in the metabolic profiles were detected in LNCaP cells grown with 
glycine. No discernible pattern was present in the plots of PLS-DA models from the spectra 
coming from cells grown in glycine or alanine, but distinct groupings could be seen in the 
spectra coming from cells grown in sarcosine and N,N-dimethylglycine. In the case of 
sarcosine, three components were generated, where the first two components explained 46.3% 
of the variation, the third of which was not statistically significant (Fig. 9) (Supplementary 
table 1). 
 
Figure 9: PLS-DA model of bucket values from LNCaP cells grown with increasing 
concentrations of sarcosine. The metabolites corresponding to the bucket values with the 
highest contributions are listed by their variable importance from left-to-right in the 1st 
component and from top-to-bottom in the 2nd component.  
Univariate statistical analysis was conducted on the individual metabolites identified using the 
multivariate statistics. These roughly corresponded to two groups; energy metabolites (Fig. 
10) and amino acid metabolites (Fig. 11). 
 Figure 10: Statistically significant differential energy metabolites in LNCaP cells grown with 
sarcosine. Glucose (A), creatine (C) and creatine phosphate (D) have increased 
concentrations in cells grown with sarcosine. Lactate (B) has increased concentration in cells 
grown with 10 µM and 25 µM of sarcosine, but not in cells grown with 50 µM of sarcosine. 
 
Figure 11: Statistically significant differential amino acid metabolites in LNCaP cells grown 
with sarcosine. A decrease in concentration of valine (A) and alanine (C) was detected in 
cells grown with sarcosine. Proline (B) had lower concentration in cells grown with 50 µM of 
sarcosine. 
In the case of LNCaP cells grown in N,N-dimethylglycine four metabolites had VIP scores 
over 1: short-chain fatty acids, creatine, creatine phosphate and uridine (Fig. 12). Out of those 
four, only the values from the buckets corresponding to short-chain fatty acids differed 
significantly (Fig. 13).  
Figure 12: PLS-DA model of bucket values from LNCaP cells grown with increasing 
concentrations of N,N-dimethylglycine. The metabolites corresponding to the bucket values 
with the highest contributions are listed by their variable importance from top-to-bottom.  
Figure 13: The 
concentrations of short-
chain fatty acids 
increased in cells grown 
with higher levels of N,N-
dimethylglycine.  
 
 
 
 
PC3 
No significant differences in the metabolic profiles were detected in PC3 cells grown with 
glycine or N,N-dimethylglycine. No discernible pattern was present in the plots of principal 
component analyses from the spectra coming from cells grown in glycine, N,N-
dimethylglycine or alanine, but distinct groupings could be seen in the spectra coming from 
cells grown in sarcosine. Two components were generated (Fig. 14) (Supplementary table 1). 
 
Figure 14: PLS-DA model of bucket values from PC3 cells grown with increasing 
concentrations of sarcosine. The metabolites corresponding to the bucket values with the 
highest contributions are listed by their variable importance from left to right in the 1st 
component and from top to bottom in the 2nd component. 
Univariate statistical analysis was conducted on the individual metabolites identified using the 
multivariate statistics (Fig. 15). 
 
 
  
Figure 15: Metabolites found to be different in PC3 cells incubated with increasing concentrations sarcosine. Malonate (A) and glucose (B) have 
increased concentrations in cells grown with sarcosine, whereas uridine (C), choline (D) and O-phosphocholine (E) have decreased 
concentrations in cells grown with sarcosine.
Intracellular levels of sarcosine 
The intracellular levels of sarcosine were briefly compared. In the cancer cell samples with 
increased concentrations of sarcosine an increase in intracellular sarcosine could be demonstrated. 
However, in benign cells there was no significant change in intracellular sarcosine (Fig. 16). 
 
Figure 16: Overview of the relative intensity of the peak corresponding to sarcosine in spectra 
coming from LNCaP, PC3 and RWPE-1 in incubated with 0 µM, 10 µM, 25 µM and 50 µM of N,N-
dimethylglycine, glycine and sarcosine respectively..  
A visual analysis of overlaid spectra was done at the area of the spectra corresponding to the singlet 
of sarcosine (2.74 ppm) (Fig. 17). Large singlet signals at the expected location for sarcosine were 
found in the spectra coming from LNCaP and PC3 grown with high concentrations of sarcosine. No 
peak was found at the expected location for sarcosine in RWPE-1. No peak corresponding to 
sarcosine was found in any cell line from samples coming from cells grown with additional glycine, 
N,N-dimethylglycine or alanine either. 
 
Figure 17: Overlaid spectra from samples of LNCaP-cells, PC3-cells and RWPE-1 cells with 0 
μM-, 10 μM-, 25 μM-, and 50 μM of added sarcosine, focused on the region of the spectra where a 
singlet from sarcosine is expected to be. The grey line in the screen capture from RWPE-1 shows 
where the centroid of the singlet coming from sarcosine should be. 
 
Discussion 
The goal of this project was to determine if treatment with sarcosine had a metabolic effect on 
malignant prostate epithelial cells and benign prostate epithelial cells which can explain previously 
observed effects on prostate cancer progression. Using an NMR metabolomics approach we 
detected a metabolic shift in both cancer cell lines tested when grown with sarcosine. Two cancer 
cell lines were used, LNCaP, an androgen-sensitive cell line, and PC3, an androgen insensitive cell 
line. The metabolic shifts of these two cell lines were similar but not identical. In both malignant 
cell lines, the concentration of glucose was increased when sarcosine was added. The 
concentrations of alanine and valine were reduced by the sarcosine treatment in both cancer cell 
lines. On top of the metabolic changes that the cancer cell lines had in common there were unique 
features of the metabolic effect on each cell type. In PC3 cells, the concentrations of choline and O-
phosphocholine were reduced upon addition of sarcosine. In LNCaP cells, the concentrations of 
creatine and creatine phosphate were higher upon addition of sarcosine, matching the concentration 
increase of glucose. LNCaP cells also had markedly reduced levels of alanine and valine.  
 
The increase in the concentration of glucose is an intriguing finding. Oxidative stress as a result of 
glucose deprivation is a common way that cells become apoptotic, especially during metastasis  
(Piskounova et al., 2015). A tantalizing speculative interpretation of the data generated in this report 
is that sarcosine prevents apoptosis or growth inhibition signaling by keeping the levels of glucose 
high. A different interpretation of the increase in glucose concentration is that the increased 
presence of glucose allows the cells to grow faster due to the glucose being used for biosynthetic- or 
energetic purposes. 
 
Another interesting finding is the fact that the levels of uridine decrease in PC3-cells grown with 
sarcosine. Previous research has shown that the most upregulated gene in response to incubation 
with sarcosine in PC3 cells is the gene encoding thymidylate synthetase (Heger et al., 2016). This 
protein is responsible for maintaining pyrimidine concentrations, specifically thymidine 
concentrations, through conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP) (Fig. 18). It is possible that the levels of uridine in PC3 cells decrease as 
thymidylate synthetase converts it into thymidine. This finding is also in line with the other findings 
reported by Heger et al, namely that many of the other genes upregulated by the presence of 
sarcosine are involved with cell cycle progression. Progression through the cell cycle necessitates 
utilizing thymidine for DNA replication. This increase in the need for thymidine could potentially 
account for the increase in consumption of uridine found in our data. 
 
 Figure 18: Schematic of the reaction catalyzed by thymidylate synthase. A methyl-group needs to be 
donated by 5,10-CH2 THF which is added onto activated deoxyuridine (dUMP). 
 
No metabolic shift was detected in RWPE-1, the benign prostate epithelial cell lines used. We also 
examined the ability of metabolites similar to sarcosine to induce metabolic shifts. Sarcosine was 
present in PC3 cells and LNCaP cells grown in sarcosine, but not in RWPE-1 cells. It is not known 
whether this was the reason that no metabolic effect was detected was because there was no 
sarcosine present in the cells. An interesting point to consider is that in previous research, where 
effects on sarcosine accumulation could be shown in benign cells, sarcosine accumulation was 
achieved by genetic manipulation of the genes responsible for maintaining the levels of sarcosine 
whereas in our experiment the sarcosine was added to the growth medium.  
 
In the research presented in 2009 by Sreekumar et al it was noted that both sarcosine and glycine 
could induce an invasive phenotype when glycine could be converted into sarcosine (Sreekumar et 
al., 2009). We could not detect any metabolic shifts as a result of adding increasing concentrations 
of glycine. Sreekumar and colleagues also saw a phenotypic difference when benign cells were 
grown with sarcosine. However, we did not see a metabolic shift in benign cells. One reason we 
could not see an effect from glycine or alanine could be that we incubated the cells for 48 hours 
instead of the 24 hour incubation that Sreekumar and colleagues did in their experiments. Both 
glycine and alanine have high rates of turnover in the cell. The turnover rates of sarcosine and N,N-
dimethylglycine are not known and most likely vary from one cell type to another, but since they 
are not being integrated into protein it is probable that their rates are considerably lower. Pools of 
both alanine and glycine are high in human cells (glycine = 325.4 ± 126.8 μM, alanine = 427.2 ± 
84.4 μM) compared to both sarcosine and N,N-dimethylglycine (Psychogios et al., 2011). Since the 
amount added was the same in absolute terms for each amino acid, the amount in proportion to the 
natural pools were considerably different. It should also be said that the physiological concentration 
of sarcosine in blood in healthy adults is 0.5-10 μM and that anything above 10 μM is indicative of 
sarcosinemia. Cancer cells are capable of altering this level to some extent, but 50 μM sarcosine 
might not be physiologically relevant. 
 
NMR spectroscopy was used for the analyses conducted in this study. While reliable, NMR is not as 
sensitive as for instance mass spectrometry and a limitation of this study is the number of 
metabolites that it captures. It is possible that many metabolites with lower concentrations were 
dramatically affected but that they were not captured in the analysis. Analyzing the samples with 
mass spectrometry will give information on the presence and concentrations of more metabolites, as 
well as aid in the identification of the metabolites whose identity was not certain in this analysis. It 
would also be prudent to incubate the cells with their respective treatments for 24 hours instead of 
48 hours in order to capture changes caused by metabolites that have higher turnover rates, if such 
changes occur.  
 
Conclusion 
Sarcosine has previously been shown to be able to drive prostate cancer progression. The goal of 
this experiment was to explore potential mechanistic explanations for how sarcosine can induce the 
phenotypic alterations associated with prostate cancer progression. Specifically, we wanted to know 
if sarcosine could cause a metabolic shift in the metabolism of prostate cancer cells. We found that 
this is indeed the case. The metabolites found to be differential are not connected by a single 
pathway and the relationship seems to be systemic, rather than specific. Broad, important pathways 
such as energy metabolism, amino acid metabolism, nucleotide metabolism and mitochondrial 
metabolism were affected. While this does not represent a complete mechanistic explanation for 
how sarcosine drives prostate cancer progression, it offers important clues to be pursued in the 
future. 
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Supplementary data 
Supplementary table 1: Model metrics for the PLS-DA models used to identify differential metabolites. *Not significant. 
Model Component R2X R2X (cum) R2Y R2Y (cum) Q2 Q2 (cum) Significance 
PC3 Sarcosine 1st component 0.273 0.273 0.233 0.233 0.0948 0.0948 R1 
 2nd component 0.231 0.504 0.0824 0.315 -0.169 0.00425 R2 
LNCaP Sarcosine 1st component 0.222 0.222 0.276 0.276 0.159 0.159 R1 
 2nd component 0.241 0.463 0.179 0.456 0.159 0.292 R1 
LNCaP  
N,N-Dimethylglycine 1st component 0.288 0.288 0.221 0.221 0.13 0.13 R1 
LNCaP Alanine 1st component 0.189 0.189 0.23 0.23 0.0693 0.0693 NS* 
Supplementary table 2: Buckets used for univariate statistical analysis, the signal which that bucket corresponds, the VIP- and VIP-cv values from the multivariate 
model and the P-values from the ANOVA.* Not significant. 
Metabolite  Bucket Signal (ppm) VIP VIP – cv P-value in ANOVA 
Valine  1.055 1.0485 - 1.0530 2.18 (LNCaP1st comp.) 1.15 0.013 
    2.55 (PC3 1st comp.) 1.36 0.031 
Glucose  3.495 3.4910 - 3.505 2.53 (LNCaP 1st comp.) 1.08 0.005 
    2.86 (PC3 1st comp.) 1.44 < 0.001 
Alanine  1.475 1.4695 - 1.4805 5.00 (LNCaP 1st comp.) 1.09 < 0.001 
    1.5296 (PC3 1st comp.) 1.06 < 0.001 
Creatine  3.945 3.945 - 3.951 2.95 (LNCaP 1st comp.) 1.19 < 0.001 
Creatine phosphate  3.955 3.952 - 3.9595 2.12 (LNCaP 1st comp.) 0.89 < 0.001 
Acetate  1.925 1.9145 - 1.9305 9.02 (LNCaP 1st comp.) 1.19 0.052* 
Lactate  1.325 1.3295 - 1.3215 6.01 (LNCaP 2nd comp.) 2.38 0.006 
Proline  4.135 4.1310 - 4.1355 2.75 (LNCaP 2nd comp.) 0.91 0.041 
SCFA  1.285 1.259 - 1.313 6.20 (LNCaP DMG 1st comp.) 2.61 < 0.001 
Uridine  7.875 7.8680 - 7.8765 2.01 (PC3 1st comp.) 0.87 < 0.001 
Malonate  3.115 3.106 - 3.1225 3.09 (PC3 1st comp.) 1.07 < 0.001 
Choline  3.205 3.1975 - 3.2095 7.98 (PC3 1st comp.) 4.44 < 0.001 
O-phosphocholine  3.225 3.2265 - 3.234 4.43 (PC3 1st comp.) 3.06 < 0.001 
